Latest Conference Articles

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.

The study presented at AAO provides an update on previously shared 6-month data from earlier this year.

Raymond Douglas, MD, PhD, discusses data that demonstrate the benefit of teprotumumab in patients with all levels of thyroid eye disease.

Edmund Tsui, MD, talks the new AAO 2020 virtual format as well as presentations that have particularly caught his attention.

Longer studies are needed to determine the effectiveness and durability of CDI interventions.

A secukinumab researcher explains why the practice may become the "next stethoscope" of medicine.

New findings show a unique series of markers could indicate particular black SLE patient risks.

Researchers have been unable to leverage new technology for ADHD screening.

Dr. David Goodman discusses the gaps in ADHD treatment.

A systematic review suggests patients taking immunosuppressive therapy may not be at as heightened risk of infection as previously thought.

An interview with a study author on the promising findings, and the use of ultrasonography in assessing psoriatic arthritis treatment.

Children hospitalized from the condition face a 14-fold increased risk of MACE.

The world is suddenly fixed on the field's most promising agents for an unprecedented virus. It's created a unique situation for specialists to collaborate.

The common rheumatic drug was found in a cohort analysis to be linked to greater regional TB outbreaks.

Researchers find 1 lipid class and 6 miRNAs differed significantly between different treatment groups.

It is possible to diagnose patients with ADHD as young as 2 years old.

AXS-05 significantly relieved agitation, demonstrating a change from baseline in the CMAI total score of 15.4 compared to 11.5 for the placebo.

Less than 2% of surveyed families with rheumatic-disease children had reported a COVID-19 case in the early pandemic—and even fewer had physician-confirmed symptoms.

Treatment for ADHD is similar for adolescents and adult patients.

Dr. David Goodman will present 5 times during NEI about different ADHD issues and topics.

In the study, investigators tested the impact of the study drug in a rerandomized patient population that previously received a placebo.

A discussion on how the pandemic has burdened and, in some ways, bettered the very involved specialty.

A large portion of communication is non-verbal.

Clinicians rated 82% of the patients receiving the study drug and 46% in the placebo group as either much improved or very much improved on the Clinical Global Impression of Improvement scale.

Attempts to use neuroimaging to screen for ADHD in the past have failed.

Both methylphenidate PRC-063 and lisdexamfetamine led to improved performances for drivers with ADHD.

In new data presented at ACG 2020, investigators report on the clinical characteristics and outcomes of chronic pancreatitis patients with CDI.

Rifaximin and lactulose did not result in clinically relevant changes to fecal microbial antibiotic susceptibility profiles.